MX2022010549A - Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras. - Google Patents
Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras.Info
- Publication number
- MX2022010549A MX2022010549A MX2022010549A MX2022010549A MX2022010549A MX 2022010549 A MX2022010549 A MX 2022010549A MX 2022010549 A MX2022010549 A MX 2022010549A MX 2022010549 A MX2022010549 A MX 2022010549A MX 2022010549 A MX2022010549 A MX 2022010549A
- Authority
- MX
- Mexico
- Prior art keywords
- bispecific antibodies
- effectively
- therapeutic intervention
- targeting molecules
- potential pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981990P | 2020-02-26 | 2020-02-26 | |
| US202062990330P | 2020-03-16 | 2020-03-16 | |
| US202063094838P | 2020-10-21 | 2020-10-21 | |
| PCT/US2021/019685 WO2021173844A1 (en) | 2020-02-26 | 2021-02-25 | C19 c38 bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010549A true MX2022010549A (es) | 2022-11-16 |
Family
ID=77463398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010549A MX2022010549A (es) | 2020-02-26 | 2021-02-25 | Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras. |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US11299551B2 (https=) |
| EP (1) | EP4110818A1 (https=) |
| JP (1) | JP7811176B2 (https=) |
| KR (1) | KR20220159989A (https=) |
| CN (1) | CN115515980A (https=) |
| AU (1) | AU2021226582A1 (https=) |
| CA (1) | CA3173257A1 (https=) |
| IL (1) | IL295896A (https=) |
| MX (1) | MX2022010549A (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295896A (en) * | 2020-02-26 | 2022-10-01 | Biograph 55 Inc | c19 c38 bispecific antibodies |
| CN115850479B (zh) * | 2021-09-16 | 2025-08-12 | 盛禾(中国)生物制药有限公司 | 一种抗cd24抗体或其抗原结合片段及其应用 |
| JP2026510999A (ja) | 2023-03-21 | 2026-04-10 | バイオグラフ ５５，インク． | Ｃｄ１９／ｃｄ３８多重特異性抗体 |
| CN120648654A (zh) * | 2024-03-13 | 2025-09-16 | 深圳太力生物技术有限责任公司 | 重组细胞的制备方法、重组细胞及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007234621B2 (en) * | 2001-01-31 | 2010-08-26 | Biogen Idec Inc. | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| US8193318B2 (en) * | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| EP3569245A1 (en) | 2006-09-26 | 2019-11-20 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2445530B1 (en) * | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| KR101911438B1 (ko) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
| WO2014191113A1 (en) | 2013-05-28 | 2014-12-04 | Numab Ag | Novel antibodies |
| KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
| BR112016015140A2 (pt) | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| CN110655582B (zh) | 2015-01-08 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
| WO2017011342A1 (en) | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| IL262241B2 (en) | 2016-04-13 | 2024-05-01 | Sanofi Sa | Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases |
| EP3481410A2 (en) | 2016-07-08 | 2019-05-15 | Paul C. Tumeh | Compositions and treatment methods for cancer immunotherapy |
| CA3032430A1 (en) | 2016-08-16 | 2018-02-22 | Epimab Biotherapeutics, Inc. | Monovalent asymmetric tandem fab bispecific antibodies |
| US20200385478A1 (en) | 2018-01-05 | 2020-12-10 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
| RU2020135920A (ru) | 2018-04-05 | 2022-05-05 | Новартис Аг | Триспецифические связывающие молекулы против форм рака и пути их применения |
| WO2019197979A1 (en) | 2018-04-10 | 2019-10-17 | Y-Biologics Inc. | Cell engaging binding molecules |
| JP7695698B2 (ja) | 2019-01-14 | 2025-06-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 細胞内部移行をモジュレートするための組成物および方法 |
| US20230039520A1 (en) | 2020-01-15 | 2023-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Pericyte-sparing therapy |
| WO2021173844A1 (en) | 2020-02-26 | 2021-09-02 | Biograph 55, Inc. | C19 c38 bispecific antibodies |
| IL295896A (en) * | 2020-02-26 | 2022-10-01 | Biograph 55 Inc | c19 c38 bispecific antibodies |
| AU2022332971A1 (en) | 2021-08-25 | 2024-03-21 | Biograph 55, Inc. | Methods of treating cancers associated with immunosuppressive b cells |
| US20240352156A1 (en) | 2021-08-25 | 2024-10-24 | Biograph 55, Inc. | Antibodies targeting immunosuppressive b cells |
| JP2026510999A (ja) | 2023-03-21 | 2026-04-10 | バイオグラフ ５５，インク． | Ｃｄ１９／ｃｄ３８多重特異性抗体 |
-
2021
- 2021-02-25 IL IL295896A patent/IL295896A/en unknown
- 2021-02-25 EP EP21713268.7A patent/EP4110818A1/en active Pending
- 2021-02-25 MX MX2022010549A patent/MX2022010549A/es unknown
- 2021-02-25 KR KR1020227032841A patent/KR20220159989A/ko active Pending
- 2021-02-25 CA CA3173257A patent/CA3173257A1/en active Pending
- 2021-02-25 JP JP2022552176A patent/JP7811176B2/ja active Active
- 2021-02-25 CN CN202180031216.2A patent/CN115515980A/zh active Pending
- 2021-02-25 AU AU2021226582A patent/AU2021226582A1/en active Pending
- 2021-04-13 US US17/229,751 patent/US11299551B2/en active Active
-
2022
- 2022-03-02 US US17/685,206 patent/US12509527B2/en active Active
- 2022-03-02 US US17/685,201 patent/US12540194B2/en active Active
- 2022-03-02 US US17/685,216 patent/US20220185908A1/en not_active Abandoned
-
2025
- 2025-12-11 US US19/417,172 patent/US20260103536A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL295896A (en) | 2022-10-01 |
| CA3173257A1 (en) | 2021-09-02 |
| US20260103536A1 (en) | 2026-04-16 |
| US20220185906A1 (en) | 2022-06-16 |
| US12540194B2 (en) | 2026-02-03 |
| KR20220159989A (ko) | 2022-12-05 |
| US12509527B2 (en) | 2025-12-30 |
| US20220185908A1 (en) | 2022-06-16 |
| EP4110818A1 (en) | 2023-01-04 |
| US11299551B2 (en) | 2022-04-12 |
| US20220185907A1 (en) | 2022-06-16 |
| CN115515980A (zh) | 2022-12-23 |
| JP2023516195A (ja) | 2023-04-18 |
| JP7811176B2 (ja) | 2026-02-04 |
| AU2021226582A1 (en) | 2022-10-13 |
| US20220363774A2 (en) | 2022-11-17 |
| US20210269545A1 (en) | 2021-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010549A (es) | Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras. | |
| AU2019225237A8 (en) | Diagnostic methods using anti-MUC1* antibodies | |
| MX2013012285A (es) | Anticuerpo anti-b7-h3. | |
| SG195196A1 (en) | Dual targeting | |
| WO2023031623A3 (en) | Synthesis of bicycle toxin conjugates, and intermediates thereof | |
| MX2024010244A (es) | Uso de un inhibidor del receptor de interleucina-4 (il-4r) para tratar la dermatitis atopica. | |
| BR112018006016A2 (pt) | intermediário de ligante-droga, compostos conjugados de anticorpo-droga, composições farmacêuticas, métodos para tratar câncer, método de produção de um composto conjugado e conjugado de anticorpo-droga | |
| MX2018011519A (es) | Agentes de alta afinidad dirigidos a antígeno de membrana específico de próstata para endoradioterapia de cáncer de próstata. | |
| MA35724B1 (fr) | Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production. | |
| UA115034C2 (uk) | Імунокон'югат для застосування в лікуванні раку або запального порушення | |
| MX2009006082A (es) | Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3). | |
| PH12014501122A1 (en) | Methods of treatment using an antibody against interferon gamma | |
| MA31564B1 (fr) | Inhibition par arni de l'expression du canal alpha-enac | |
| MX361218B (es) | Análogos de spliceostatina. | |
| MX2009008461A (es) | Variantes geneticas que contribuyen a riesgo de cancer de prostata. | |
| MX2021009138A (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco. | |
| EA201400249A1 (ru) | Ингибиторы nedd8-активирующего фермента | |
| EA201491286A1 (ru) | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| WO2020219743A3 (en) | Use of an anti-cd19 antibody to treat autoimmune disease | |
| EA201892438A1 (ru) | 6-АМИНОПИРИДИН-3-ИЛТИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγt | |
| PH12019501678A1 (en) | Potassium channel modulators | |
| IL290249A (en) | A method for treating muscular dystrophy by targeting the lama1 gene | |
| MX2015006616A (es) | Doble direccion. | |
| SA521431274B1 (ar) | مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 |